Review of boceprevir and telaprevir for the treatment of chronic hepatitis C

Canadian Journal of Gastroenterology

Volumn 26, Issue 4, 2012, Pages 205-210

  Wilby, Kyle J ^a   Partovi, Nilufar ^a,b   Ford, Jo Ann E ^c   Greanya, Erica D ^a,b   Yoshida, Eric M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c Gordon and Leslie Diamond Health Care Centre Vancouver Coastal Health   (Canada)

Author keywords

Boceprevir; Hepatitis C; Protease inhibitors; Telaprevir; Viral hepatitis

Indexed keywords

ATORVASTATIN; BOCEPREVIR; CYCLOSPORIN; DARUNAVIR; EFAVIRENZ; ETHINYLESTRADIOL; FOSAMPRENAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TACROLIMUS; TELAPREVIR;

ANEMIA; DIARRHEA; DRUG MECHANISM; DYSGEUSIA; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84860355165     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/751057     Document Type: Review

References (30)

1. Rosen HR. Chronic Hepatitis C infection. N Engl J Med 2011;364:2429-38.
2. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatol 1997;26:34S-38S. (Pubitemid 27388069)
3. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139:1593-601.
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65. (Pubitemid 32913521)
5. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribvirin dose. Ann Intern Med 2004;140:346-55.
6. Yoshida EM, Sherman M, Bain VG, et al. Re-treatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol 2009;23:180-84.
7. Vermehren J, Sarrazin C. New HCV therapies on the horizon. Clinical Microbiol Infect 2011;17:122-34.
8. Jazwinski AB, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol 2011;7:154-62.
9. Meurs EF, Breiman A. The interferon inducing pathways and the hepatitis C virus. World J Gastroenterol 2007;13:2446-54. (Pubitemid 46929500)
10. Merck & Co. Victrelis (boceprevir) Product Monograph. Whitehouse Station, NJ 2011. 〈www.merck.ca/assets/en/pdf/ products/VICTRELIS-PM-E. pdf〉 (Accessed August 5, 2011).
11. Vertex Pharmaceuticals Inc. Incivek (telaprevir) Product Monograph. Cambridge, Massachusetts, 2011.
12. McHutchinson JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for trement of hepatitis C infection. N Engl J Med 2009;361:5801-93.
13. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterol 2007;132:1270-8. (Pubitemid 46627577)
14. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16.
15. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of hepatitis C genotype 1 patients responding to 24 weeks of peginteferon alpha-2a (40 kD)/ribavirin treatment. Hepatology 2006;43:954-60. (Pubitemid 43724620)
16. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon apha-2b plus ribavirin in patients with chronic hepatitis C infection with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103. (Pubitemid 41772522)
17. Poordad F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
18. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
19. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatol 2007;46:640-8. (Pubitemid 47436108)
20. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008;49:163-9.
21. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002. (Pubitemid 44498690)
22. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38.
23. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303.
24. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-68.
25. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
26. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
27. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
28. Garg V, van Heeswijk R, Lee J, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54:20-7.
29. Haque M, Scudamore CH, Steinbrecher UP, et al. Liver transplantation: Current status in British Columbia. Br Col Med J 2010;52:205-12.
30. Foster GR, Hezode C, Bronowicki J-P, et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: Final results of study C209. J Hepatol 2010;52:S27.